+Compare
BIO
Stock ticker:
NYSE
AS OF
Jun 24 closing price
Price
$508.15
Change
+$2.25 (+0.44%)
Capitalization
14.84B

BIO Price Prediction, Bio-Rad Laboratories IncClass A AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar
AI
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EDT Jun 24, 2022

BIO's RSI Oscillator ascending out of oversold territory

The RSI Oscillator for BIO moved out of oversold territory on June 15, 2022. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 25 similar instances when the indicator left oversold territory. In 21 of the 25 cases the stock moved higher. This puts the odds of a move higher at 84%.

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 53 cases where BIO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BIO advanced for three days, in of 348 cases, the price rose further within the following month. The odds of a continued upward trend are .

BIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 266 cases where BIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on June 10, 2022. You may want to consider selling the stock, shorting the stock, or exploring put options on BIO as a result. In of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for BIO turned negative on June 10, 2022. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .

BIO moved below its 50-day moving average on June 09, 2022 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for BIO crossed bearishly below the 50-day moving average on June 13, 2022. This indicates that the trend has shifted lower and could be considered a sell signal. In of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.474) is normal, around the industry mean (7.082). P/E Ratio (3.643) is within average values for comparable stocks, (90.421). Projected Growth (PEG Ratio) (4.432) is also within normal values, averaging (4.111). Dividend Yield (0.000) settles around the average of (0.021) among similar stocks. P/S Ratio (5.263) is also within normal values, averaging (89.714).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

AI
A.I.Advisor
published price charts
AI
A.I. Advisor
published Earnings

BIO is expected to report earnings to fall 33.40% to $3.29 per share on August 04

Bio-Rad Laboratories IncClass A BIO Stock Earnings Reports
Q2'22
Est.
$3.29
Q1'22
Beat
by $1.57
Q4'21
Beat
by $0.36
Q3'21
Beat
by $1.27
Q2'21
Beat
by $0.88
The last earnings report on April 28 showed earnings per share of $4.94, beating the estimate of $3.37. With 32.91K shares outstanding, the current market capitalization sits at 14.84B.
AI
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Intuitive Surgical (NASDAQ:ISRG), Edwards Lifesciences Corp (NYSE:EW), Boston Scientific Corp (NYSE:BSX), IQVIA Holdings (NYSE:IQV), Illumina (NASDAQ:ILMN), Align Technology (NASDAQ:ALGN), Exact Sciences Corp (NASDAQ:EXAS), Guardant Health (NASDAQ:GH).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 5.49B. The market cap for tickers in the group ranges from 775 to 3.9T. MKYSF holds the highest valuation in this group at 3.9T. The lowest valued company is BIIO at 775.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was 9%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was -19%. NRCD experienced the highest price growth at 2,122%, while NGMDF experienced the biggest fall at -39%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was -26%. For the same stocks of the Industry, the average monthly volume growth was 46% and the average quarterly volume growth was 13%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 71
Price Growth Rating: 58
SMR Rating: 69
Profit Risk Rating: 84
Seasonality Score: 14 (-100 ... +100)
AI

View a ticker or compare two or three

AI
A.I. Advisor
published General Information

General Information

a manufacturer of life science research products and clinical diagnostics

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
1000 Alfred Nobel Drive
Phone
+1 510 724-7000
Employees
7900
Web
https://www.bio-rad.com

Interesting Tickers

1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SUZ9.140.38
+4.28%
Suzano SA
CRNT2.210.09
+4.25%
Ceragon Networks Ltd
CENTA40.610.05
+0.12%
Central Garden & Pet Company
IDT25.06-0.32
-1.24%
IDT Corp
AYLA1.07-0.18
-14.40%
Ayala Pharmaceuticals

BIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIO has been closely correlated with DHR. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if BIO jumps, then DHR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIO
1D Price
Change %
BIO100%
+0.51%
DHR - BIO
76%
Closely correlated
+0.69%
TMO - BIO
75%
Closely correlated
+0.99%
A - BIO
73%
Closely correlated
+2.07%
WST - BIO
72%
Closely correlated
+0.94%
IQV - BIO
71%
Closely correlated
+1.06%
More